Company intelligence / Profile preview

4C Biomed

London, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

The lead program, anti-4CB1, is a first-in-class monoclonal antibody targeting HVEM. It blocks both HVEM-BTLA and HVEM-CD160 interactions. Anti-4CB1 has shown superior cytotoxicity compared to anti-PD1 in ex-vivo patient samples across various solid cancers and is well tolerated in GLP toxicity studies in cynomolgus monkeys. The company is ready for clinical trials and seeks licensing or Series A funding

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBiological products (general)
Industry: Biotech

Drug pipeline

1 asset

4CB-1

Unknown

Partnerships

Sheba Medical Center/ARC Innovation (spin-off origin/investor)

Beyond the preview

Go deeper on 4C Biomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4C Biomed.

Explore the full profile